Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease is a research paper published in Pharmaceuticals (2023). On theSindex it has a DataRank of 0. It has been cited 9 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: HL133474
National Institutes of Health
Grant: HL144909
National Institutes of Health
Grant: 5K08HL133474-04
The role of NFATc3 in altered hypoxic pulmonary vasoconstriction during acute lung injury
National Institutes of Health
Grant: 1T32HL144909-01A1
Postdoctoral Training Program in Pulmonary and Critical Care Translational Research
Fields of Study
Keywords